1. Protein Tyrosine Kinase/RTK
  2. Ephrin Receptor

Ephrin Receptor

Ephrin receptors (Ephs) are a group of receptors that are activated in response to binding ephrin. Ephs form the largest known subfamily of receptor tyrosine kinases (RTKs). Both Ephs and their corresponding ephrin ligands are membrane-bound proteins that require direct cell-cell interactions for Eph receptor activation. Eph/ephrin signaling has been implicated in the regulation of a host of processes critical to embryonic development including axon guidance, formation of tissue boundaries, cell migration, and segmentation. Additionally, Eph/epherin signaling has recently been identified to play a critical role in the maintenance of several processes during adulthood including long-term potentiation, angiogenesis, and stem cell differentiation and cancer. The ability of Ephs and ephrins to mediate a variety of cell-cell interactions places the Eph/ephrin system in an ideal position to regulate a variety of different biological processes during embryonic development.

Ephrin Receptor Related Products (3):

Cat. No. Product Name Effect Purity
  • HY-18007
    ALW-II-41-27 Inhibitor 99.73%
    ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment.
  • HY-16265
    JI-101 Inhibitor 99.78%
    JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4). JI-101 inhibits angiogenesis, and subsequently tumor growth. [1]
  • HY-13258
    NVP-BHG712 Inhibitor
    NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.